Teva Pharmaceuticals CEO Vigodman Is Stepping Down

Key Speakers At 16th Nikkei Global Management Forum 2014

Health Teva Pharmaceuticals CEO Vigodman Is Stepping Down The chief executive of Teva Pharmaceutical Industries, the world’s biggest maker of generic drugs, stepped down after three years following a series of strategic stumbles and legal and

Picture taken on January 15, 2012 in Lil

Health This 62-year-old drug just got 5,000% more expensive Daraprim, a treatment for malaria and toxoplasmosis, is now 5,455% more expensive than it was only two months ago. The drug’s price jumped from $13.50 to $750 a pill, bringing the annual cost

Features This is the fastest growing company in the U.S.The top company on this year’s Fastest Growing Companies list rocketed up the charts from No. 29 last year — and you may not even know its name. It isn’t a sexy Silicon Valley startup or

Production At The Merck KGaA Pharmaceutical Plant

Finance Why drug companies are betting big on ‘pharmerging’ countries So-called pharmerging nations–developing countries where use of pharmaceuticals is growing rapidly–are expected to see the fastest growth in total drug spending over the next three years,

Finance Teva in talks to buy Allergan’s generic drug business Teva Pharmaceutical Industries Ltd is in advanced talks to buy Allergan Plc’s generic drug business following a thus far unsuccessful effort to acquire peer Mylan NV, according to a person

Features The pharma M&A party is still in full swing, as Endo snaps up Par The takeover boom in the pharmaceuticals industry just can’t stop. Endo International Plc ENDP said Monday it’s buying generic drugmaker Par for a total of $8.05 billion worth of cash,

Clashes in Baltimore over death of Freddie Gray

Features Baltimore riots, Google, and Twitter earnings — 5 things to know today Hello friends and Fortune readers. Wall Street stock futures are mixed to lower this morning as quarterly earnings reports keep rolling in. Shares of Apple AAPL are higher Tuesday, after beating

Finance Teva offers to buy rival Mylan for $40 billion to create generics giant Teva Pharmaceuticals has proposed buying rival Mylan for $40 billion in cash and stock, as the Israel-based drugmaker looks to gain dominance among generic pharmaceutical companies. Teva TEVA is

Finance Mylan goes big with $29 billion offer to buy Perrigo Generic drugmaker Mylan has proposed buying Perrigo for about $29 billion in cash and stock in what would be the biggest pharmaceutical deal of the year so far. Mylan MYL will pay $205 per share in

CEO Daily NewsletterSign up for CEO Daily to get must-read business news fit for the corner office—plus more.View Sample

Most Popular on FORTUNE

Widespread Disdain for ‘Pharma Bro’ Martin Shkreli is Making Jury Selection Difficult

Former Turing Pharmaceuticals CEO Martin Shkreli On Trial For Securities Fraud

Widespread Disdain for ‘Pharma Bro’ Martin Shkreli is Making Jury Selection Difficult

This Ukrainian Company Is Likely Behind the Ransomware Wave

Miranda Kerr Hands Over $8.1 Million in Jewelry Linked to Corruption Case

"Rei Kawakubo/Comme des Garcons: Art Of The In-Between" Costume Institute Gala - Sightings

Miranda Kerr Hands Over $8.1 Million in Jewelry Linked to Corruption Case

The Seattle Minimum Wage Study Is Utter B.S.

Everything to Know About Today’s Worldwide Ransomware Attack

FRANCE-INTERNET-INFORMATION-TECHNOLOGY-SECURITY-COMPUTER

Everything to Know About Today’s Worldwide Ransomware Attack

Customer Service Site Map Privacy Policy Advertising Ad Choices Terms of Use Your California Privacy Rights Careers

All products and services featured are based solely on editorial selection. FORTUNE may receive compensation for some links to products and services on this website.

Quotes delayed at least 15 minutes. Market data provided by Interactive Data. ETF and Mutual Fund data provided by Morningstar, Inc. Dow Jones Terms & Conditions: http://www.djindexes.com/mdsidx/html/tandc/indexestandcs.html. S&P Index data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions